Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp has demonstrated a consistent growth trend in utilization, with an average increase of approximately 6.1% per quarter over the last six quarters, signaling rising demand for its surgical robotic systems. The company is also effectively managing its operating expenses, committing to grow these costs at half the rate of its top-line growth, which suggests a clear pathway to profitability. Additionally, strong performance in capital system placements, with 58 new systems installed in the recent quarter—outpacing prior guidance—highlights the company’s robust market presence and future growth potential.

Bears say

PROCEPT BioRobotics's stock has experienced a significant decline of approximately 54% year-to-date, indicating a lack of confidence among investors despite the company's ability to exceed its internal guidance. The company faces multiple downside risks, including a potential decrease in demand for capital equipment, reduced usage of handpieces by customers, heightened competitive pressures, and unfavorable changes in reimbursement rates for its Aquablation therapy. Additionally, commentary regarding utilization and inventory has contributed to further negative sentiment, suggesting ongoing challenges that may impact future revenue growth.

PRCT has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 8 analysts, PRCT has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.